Pharmaceuticals company Terapia Ranbaxy has received from the National Drug Agency (ANM) the Manufacturing and Import Authorisation according to the EU norms and standards for its Cluj-based production unit. Prior to this authorisation, the drugs manufactured at Cluj could not have been sold on the European market without the risk of being withdrawn. "It is a first and a very important step in the process whereby we are creating, at our site in Cluj-Napoca, a powerful platform for further expansion into the EU," said Dragos Damian (photo), CEO of Terapia Ranbaxy. As a result, Terapia Ranbaxy has been granted the green light for batch testing and release activities for products manufactured outside the European Union. The drug manufactureres majority shareholder is the Indian group Ranbaxy, which purchased 96.7% of the local companyes shares last year. The commercial name of the company is Terapia Ranbaxy. With a market share of 5.6%, the company, last year, registered approximately a 50% increase in its turnover against 2005. This year Terapia will be the growth driver of Ranbaxyes profit, according to certain statements that the representatives of the Indian giant already made. For 2007, at a commercial level, the company is planning to launch more than 40 new products. In November last year, Terapia Ranbaxy announced the completion of the investment in a new logistic centre in Otopeni - Bucharest.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
